TITLE

The NCT Turin Project For Primary And Secondary Hepatic Cancer

AUTHOR(S)
Zanon, Claudio
PUB. DATE
June 2004
SOURCE
Internet Journal of Medical Technology;2004, Vol. 1 Issue 2, p15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The development of new kind of therapy in the treatment of cancer in which a surgical approach in not possible, or which does not respond to chemo or traditional radio therapy, actually is object of international interest; in particular international studies are applied to the neutron capture therapy, known as NCT. The neutron capture therapy is based on the possibility to give, using an adequate source of termic neutronic beams of sufficient intensity able to produce by opportune nuclear reactions characterised by high energetic release, the selective cellular death.
ACCESSION #
14909107

 

Related Articles

  • Tackling tumours. Czyzewski, Andrew // Engineer (00137758);4/25/2011, Vol. 296 Issue 7815, p18 

    No abstract available.

  • Small Molecule Inhibitors of Stat3 Signaling Pathway. Jinxia Deng; Grande, Fedora; Neamati, Nouri // Current Cancer Drug Targets;Feb2007, Vol. 7 Issue 1, p91 

    Constitutive activation of the Signal Transducers and Activators of Transcription 3 (Stat3) meditated signaling pathway is very important for cell growth and survival. Compelling evidence from mechanistic studies with antisense, RNA interference (RNAi), peptides, and small molecular inhibitors...

  • Macroautophagy as a Target of Cancer Therapy. Lorin, S�verine; Codogno, Patrice; Djavaheri-Mergny, Mojgan // Current Cancer Therapy Reviews;2007, Vol. 3 Issue 3, p199 

    Macroautophagy (hereafter referred as to autophagy) is a vacuolar lysosomal degradative pathway for cytoplasmic macromolecules and organelles. There is growing evidence that autophagy is controlled by tumor-regulating molecules, and that it is downregulated during the early stages of...

  • Fast neutron treatment as an alternative to radical surgery for malignant tumours of the facial area. Catterall, Mary; Blake, P.R.; Rampling, R.P. // British Medical Journal (Clinical Research Edition);12/15/1984, Vol. 289 Issue 6459, p1653 

    Evaluates the fast neutron treatment in patients with malignant tumors. Evidence of tumor regression; Concerns on the treatment duration and requirements; Occurrence of complications.

  • A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Mellor, H. R.; Ferguson, D. J. P.; Callaghan, R. // British Journal of Cancer;8/8/2005, Vol. 93 Issue 3, p302 

    The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon...

  • Current status of the molecular mechanisms of anticancer drug-induced apoptosis: The contribution of molecular-level analysis to cancer chemotherapy. Kim, Ryungsa; Tanabe, Kazuaki; Uchida, Yoko; Emi, Manabu; Inoue, Hideki; Toge, Tetsuya // Cancer Chemotherapy & Pharmacology;Nov2002, Vol. 50 Issue 5, p343 

    Apoptosis is an important phenomenon in cytotoxicity induced by anticancer drugs. Here, we review the current status of the molecular mechanisms of anticancer drug-induced apoptosis in order to assess the contribution of molecular-level analysis to cancer chemotherapy. It is apparent that the...

  • Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Scholz, Christian; Richter, Antje; Lehmann, Mario; Schulze-Osthoff, Klaus; Dörken, Bernd; Daniel, Peter T. // Oncogene;10/27/2005, Vol. 24 Issue 47, p7031 

    Arsenic trioxide (As2O3, arsenite) efficiently kills cells from various hematologic malignancies and has successfully been employed especially for the treatment of acute promyelocytic leukemia. There and in lymphoid cells, we demonstrated that As2O3 induces cell death in a caspase-2- and...

  • A Dynamical Systems Model for Combinatorial Cancer Therapy Enhances Oncolytic Adenovirus Efficacy by MEKInhibition. Bagheri, Neda; Shiina, Marisa; Lauffenburger, Douglas A.; Korn, W. Michael // PLoS Computational Biology;Feb2011, Vol. 7 Issue 2, p1 

    Oncolytic adenoviruses, such as ONYX-015, have been tested in clinical trials for currently untreatable tumors, but have yet to demonstrate adequate therapeutic efficacy. The extent to which viruses infect targeted cells determines the efficacy of this approach but many tumors down-regulate the...

  • Cellular senescence in cancer treatment: friend or foe? Kahlem, Pascal; Dörken, Bernd; Schmitt, Clemens A.; Pelicci, Pier Giuseppe // Journal of Clinical Investigation;Jan2004, Vol. 113 Issue 2, p169 

    Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics